Does your gut microbiome play a role in therapeutic outcomes?

Chro­ma Med­i­cine laid off an undis­closed num­ber of em­ploy­ees ear­li­er this week, as the pri­vate­ly held start­up fo­cus­es its re­sources on mov­ing its first epi­ge­net­ic

PHOENIX — The investigational agent riliprubart, a complement C1s inhibitor, showed encouraging activity in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), according to a phase

TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. Credit: Kinga Krzeminska via Getty Images. Ono Pharmaceutical has secured approval from